FR2861993B1 - Complexe moleculaire anti restenose pour endoprothese intracoronaire - Google Patents
Complexe moleculaire anti restenose pour endoprothese intracoronaireInfo
- Publication number
- FR2861993B1 FR2861993B1 FR0313025A FR0313025A FR2861993B1 FR 2861993 B1 FR2861993 B1 FR 2861993B1 FR 0313025 A FR0313025 A FR 0313025A FR 0313025 A FR0313025 A FR 0313025A FR 2861993 B1 FR2861993 B1 FR 2861993B1
- Authority
- FR
- France
- Prior art keywords
- drugs
- molecular complex
- iloprost
- colchicine
- restenosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Complexe Moléculaire déposé sur le « Stent » destiné à diminuer le pourcentage de Resténose après angioplastie coronarienne transluminale .L'invention consiste dans l'association sur le stent de 2 couches de polyméres associées à des drogues actives sur la Resténose :La premiére couche à base de polyethyléne etheroxide de castor permet une libération instantanée de drogues ( Colchicine , Iloprost , Allopurinol , Vitamine E )ayant une action antithrombotique , anti-inflammatoire , anti radicaux libres , antiproliférative, favorisant la réendothélialisation.La deuxiéme couche à base de poly (lactide-co-glycolide) Acid dans une proportion de 50/50 permettant une libération prolongée de drogues sur une durée de 140 jours environ (Colchicine et Iloprost) agissant sur la prolifération anarchique des cellules qui se reconstruisent et sur les phénomes thrombotiques qui pourraient survenir .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0313025A FR2861993B1 (fr) | 2003-11-06 | 2003-11-06 | Complexe moleculaire anti restenose pour endoprothese intracoronaire |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0313025A FR2861993B1 (fr) | 2003-11-06 | 2003-11-06 | Complexe moleculaire anti restenose pour endoprothese intracoronaire |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2861993A1 FR2861993A1 (fr) | 2005-05-13 |
FR2861993B1 true FR2861993B1 (fr) | 2006-01-21 |
Family
ID=34508286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0313025A Expired - Fee Related FR2861993B1 (fr) | 2003-11-06 | 2003-11-06 | Complexe moleculaire anti restenose pour endoprothese intracoronaire |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2861993B1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE339975T1 (de) * | 1993-07-19 | 2006-10-15 | Angiotech Pharm Inc | Anti-angiogener stent und verfahren zu dessen herstellung |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US6544541B1 (en) * | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US8679520B2 (en) * | 2001-10-15 | 2014-03-25 | Hemoteq Ag | Coating of stents for preventing restenosis |
-
2003
- 2003-11-06 FR FR0313025A patent/FR2861993B1/fr not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR2861993A1 (fr) | 2005-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abizaid et al. | Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial | |
Serruys et al. | The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES) | |
Topol et al. | Frontiers in interventional cardiology | |
WO2009079389A3 (fr) | Endoprothèse à élution de médicaments | |
BR0110778A (pt) | combinações de drogas úteis para prevenção de restenose | |
Verheye et al. | The sabre trial (sirolimus angioplasty balloon for coronary in-stent restenosis) angiographic results and 1-year clinical outcomes | |
EP1127582A3 (fr) | Utilisation d'un stent muni de cladribine pour la prévention de resténose | |
NZ588549A (en) | Stents having bioabsorbable layers | |
ATE251449T1 (de) | Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe | |
DE602005016044D1 (de) | Deckbeschichtung enhaltend Heparin für kontrollierte Wirkstoffabgabe | |
Raval et al. | Mechanism and in vitro release kinetic study of sirolimus from a biodegradable polymeric matrix coated cardiovascular stent | |
DE69926255D1 (de) | Bioaktive prothesen aus leitendem material beschichtet mit einem polymer und einer substanz mit immunsuppressiven , antistenosen und antithrombosen eigenschaften | |
ATE369096T1 (de) | Stent für die freisetzung von aktiven substanzen | |
WO2008118606A3 (fr) | Couche barrière en métal biodégradable pour une endoprothèse à élution de médicament | |
EP2671540A3 (fr) | Capture de cellules endothéliales progénitrices avec un dispositif médical implantable à élution de médicament | |
BR0213279A (pt) | Revestimento de stents para impedir a restenose | |
Barbato et al. | A first-in-man clinical evaluation of Ultimaster, a new drug-eluting coronary stent system: CENTURY study | |
WO2004030678A8 (fr) | Compositions polymeres contenant des agents bioactifs et procedes d'utilisation de celles-ci | |
WO2007047473A3 (fr) | Procedes d'administration d'analogues de rapamycine avec des anti-inflammatoires au moyen de dispositifs medicaux | |
Romaguera et al. | Amphilimus-vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial | |
WO2008063319A3 (fr) | Procédés d'administration d'analogues à la rapamycine avec des anti-inflammatoires au moyen de dispositifs médicaux | |
Rogers | Optimal stent design for drug delivery. | |
Maillard et al. | Evaluation of the safety and efficacy of the cobra PzF NanoCoated coronary stent in routine, consecutive, prospective, and high‐risk patients: The E‐cobra study | |
FR2861993B1 (fr) | Complexe moleculaire anti restenose pour endoprothese intracoronaire | |
Fefer et al. | Percutaneous coronary intervention in patients with haemophilia presenting with acute coronary syndrome: an interventional dilemma: case series, review of the literature, and tips for management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20080930 |
|
RN | Application for restoration | ||
FC | Favourable decision of inpi director general on an application for restauration. | ||
ST | Notification of lapse |
Effective date: 20100730 |